<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02739373</url>
  </required_header>
  <id_info>
    <org_study_id>AI006-003</org_study_id>
    <nct_id>NCT02739373</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics, Safety, Tolerability and Pharmacodynamics of BMS-986189 in Healthy Subjects</brief_title>
  <official_title>Randomized, Double-Blinded, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Pharmacodynamics of BMS-986189 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to measure the amount of study drug (BMS-986189) in the
      blood and urine and to see if BMS-986189 is safe and well-tolerated in healthy people after a
      single dose.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 18, 2016</start_date>
  <completion_date type="Actual">December 14, 2016</completion_date>
  <primary_completion_date type="Actual">December 14, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum observed concentration (Cmax)</measure>
    <time_frame>Day 1 to Day 30</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time of maximum observed concentration (Tmax)</measure>
    <time_frame>Day 1 to Day 30</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration-time curve from time zero to the time of the last quantifiable concentration (AUC(O-T))</measure>
    <time_frame>Day 1 to Day 30</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration-time curve from time zero extrapolated to infinite time (AUC(INF))</measure>
    <time_frame>Day 1 to Day 30</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Half Life (T-HALF)</measure>
    <time_frame>Day 1 to Day 30</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Total Body Clearance (CLT/F)</measure>
    <time_frame>Day 1 to Day 30</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent volume of distribution at steady state (Vss/F)</measure>
    <time_frame>Day 1 to Day 30</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Deaths leading to discontinuation</measure>
    <time_frame>Day 1 to Day 30</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse events (AEs) leading to discontinuation</measure>
    <time_frame>Day 1 to Day 30</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Serious adverse events (SAEs) leading to discontinuation</measure>
    <time_frame>Day 1 to Day 30</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Lab abnormalities leading to discontinuation</measure>
    <time_frame>Day 1 to Day 30</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">76</enrollment>
  <condition>Severe Sepsis</condition>
  <arm_group>
    <arm_group_label>BMS-986189</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Specified Dose on Specified Day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Specified Dose on Specified Day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-986189</intervention_name>
    <arm_group_label>BMS-986189</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding BMS clinical trial participation, please visit
        www.BMSStudyConnect.com

        Inclusion Criteria:

          -  Healthy, males and females, 18 to 55 years of age, inclusive

          -  Body Mass Index (BMI) of 18.0 to 30.0 kg/m2, inclusive

          -  Women of childbearing potential (WOCBP) must have negative serum pregnancy test
             (performed for all females; minimum sensitivity 25 IU/L or equivalent units of human
             chorionic gonadotropin) within 24 hours prior to start of study drug

        Exclusion Criteria:

          -  Any significant acute or chronic medical illness

          -  History of diabetes mellitus, severe hypertriglyceridemia, acute or chronic
             pancreatitis, pancreatic exocrine disorder

          -  History of autoimmune disease

          -  Any known skin condition that would affect subcutaneous dosing

          -  Positive blood screen for hepatitis C antibody (HCV Ab), hepatitis B surface antigen
             (HBsAg), or HIV -1 and HIV -2 antibody

        Other protocol defined inclusion/exclusion criteria could apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Covance Clinical Research Unit, Inc.</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx</url>
    <description>Investigator Inquiry form</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <link>
    <url>http://bms.com/studyconnect/Pages/home.aspx</url>
    <description>BMS Clinical Trial Patient Recruiting</description>
  </link>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 8, 2016</study_first_submitted>
  <study_first_submitted_qc>April 14, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 15, 2016</study_first_posted>
  <last_update_submitted>February 5, 2018</last_update_submitted>
  <last_update_submitted_qc>February 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

